Heart Transplant Market Analysis

Global Heart Transplant Market Overview

Heart Transplant Market Size was valued at USD 10.2 Billion in 2022. The Heart Transplant market Type is projected to grow from USD 11.2 Billion in 2023 to USD 24.3 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.10% during the forecast period (2023 - 2032). Cardiovascular disease patients are becoming more numerous, and the number of seniors is growing, are the key market drivers enhancing the market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Heart Transplant Market Trends

• Increasing the number of patients suffering from cardiovascular disease is driving the market growth

The demand for heart surgery and treatments is increasing as more people worldwide suffer from cardiovascular disease, which also drives up the cost of heart transplants. The demand for heart transplants is increasing due to the ageing population and the rising number of individuals with high blood cholesterol levels. Additionally, the global demand for heart transplants is rising as a result of the rising mortality rate of people dying from heart failure. Changes in lifestyle and eating habits are the main contributors to the development of cardiovascular diseases, which also drive the market for heart transplants to expand. Apart from heart transplants, which are also expected to accelerate the growth of the heart transplants therapeutics market, other procedures and treatments that use heart transplant devices include arrhythmia treatment, coronary artery bypass grafting, aneurysm repair, total artificial hearts or ventricular assist devices, etc.

One of the main factors that damages the heart muscles and results in heart failure is coronary artery disease. Poor exercise tolerance, coughing, particularly at night, shortness of breath, exhaustion, and fluid retention are a few conditions that might cause heart failure. According to a report by the International Society for Heart and Lung Transplantation, approximately 500–600 paediatric heart transplant procedures are carried out annually globally, accounting for 12% of all heart transplants. A congenital cardiac abnormality or cardiomyopathy is the main contributor to heart failure in young children.

Heart failure and coronary artery disease cases have both significantly increased during the past ten years. These cardiovascular conditions frequently necessitate a heart transplant. Thus, this is one of the key elements promoting the market for heart transplants to increase. Major market drivers for heart transplants include an increase in the number of elderly people and patients with high blood cholesterol levels. Additionally, the number of individuals dying from heart failure is increasing, which has increased demand for heart transplants worldwide. The likelihood of acquiring cardiovascular diseases is also enhanced by changes in diet and lifestyle. These elements fuel the market's expansion for cardiac transplants. Thus, driving the Heart Transplant market revenue.

Heart Transplant Market Segment Insights:

Heart Transplant Type Insights

The Heart Transplant Market segmentation, based on Type, includes ventricular assisted device, total artificial hearts and others. Ventricular assisted device segment dominated the global market in 2022. A ventricular assist device (VAD) aids in the circulation of blood from the heart's lower chambers to the body as a whole. It is used to treat heart failure or a weak heart. While the patient is awaiting other therapies, such as a heart transplant, a VAD may be utilised to keep the heart pumping. The heart can occasionally be permanently assisted by a VAD. VADs that are now approved are either placed within the body on top of the abdomen, right below the diaphragm.

Heart Transplant End User Insights

The Heart Transplant Market segmentation, based on End User, includes hospitals, cardiac institutes, and others. Hospitals segment dominated the Heart Transplant Market in 2022. The primary reason fueling the growth of this market is the rise in heart transplant surgeries being carried out in hospitals.

Figure 1: Heart Transplant Market, by End User, 2022 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Heart Transplant Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America Heart Transplant Market dominated this market in 2022 (45.80%). This is due to high healthcare costs, advanced heart transplant technology, and rising government funding for research and advancement of improved heart transplant technologies. Furthermore, North America holds the largest market share for heart transplants due to high healthcare spending, an increase in patients with coronary artery disease, cardiomyopathy, and cardiac valve disease, and other factors. Further, the U.S. Heart Transplant market held the largest market share, and the Canada Heart Transplant market was the fastest growing market in the North America region.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: HEART TRANSPLANT MARKET SHARE BY REGION 2022 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Heart Transplant market accounted for the healthy market share in 2022. This is because government financing for research and development activities aimed at releasing workable cardiac transplant devices for monitoring patients after transplant has increased. Further, the German Heart Transplant market held the largest market share, and the U.K Heart Transplant market was the fastest growing market in the European region

The Asia Pacific Heart Transplant market is expected to register significant growth from 2023 to 2032. The heart transplant market has grown most rapidly in the Asia Pacific area in recent years. Heart transplant costs are far lower in developing nations like China and India than in industrialised ones, which draws many patients from around the world to the area. Additionally, it is anticipated that increased demand for high-quality heart transplant devices would encourage the use of cutting-edge technology, which will fuel market expansion for these devices. Moreover, China’s Heart Transplant market held the largest market share, and the Indian Heart Transplant market was the fastest growing market in the Asia-Pacific region.

Heart Transplant Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Heart Transplant market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Heart Transplant Industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Heart Transplant Industry to benefit clients and increase the market sector. In recent years, the Heart Transplant Industry has offered some of the most significant advantages to medicine. Major players in the Heart Transplant market, including Apaxis Medical, Inc., CardiacAssist Inc., SynCardia Systems, LLC, Optum Inc., CARMAT, HeartWare International Inc., Thoratec Corporation, and Calon Cardio, are attempting to increase market demand by investing in research and development operations.

Biopharmaceuticals are discovered, developed, produced, and sold by Pfizer Inc. The business sells goods to cure a range of ailments, including cancer, inflammation, rare diseases, metabolic, cardiovascular, and metabolic and pain disorders, as well as women's health issues. Additionally, it offers contract manufacturing services, sterile injectable drugs, biosimilars, active pharmaceutical ingredients (APIs), and medicines. Pfizer offers its goods through distributors, merchants, pharmacies, hospitals, private physician offices, clinics, and public institutions. India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US are all home to significant manufacturing facilities for it. The company ships its goods to Europe, Africa, the Middle East, Asia-Pacific, Australia, and North and South America. Pfizer's U.S. headquarters are in New York. Following FDA approval, Pfizer, Inc. released two new medications in May 2019 under the names Vyndaqel and Vyndamax. These medicines can be used to treat heart failure-causing cardiomyopathy or inherited transthyretin-mediated amyloidosis.

Dedicated to the discovery, creation, and commercialization of diagnostic remedies for transplant patients, CareDx Inc (CareDx) is a diagnostics business. AlloSure, AlloMap, Qtype, Olerup SSP and SBT, Trusight, AlloSeq cfDNA, HeartCare, KidneyCare, Ottr Organ, Ottr Cellular, XynQAPI, TxAccess, XynCare, AlloCare, AlloCell, and AlloSeq HCT are a few of its products. The business offers testing solutions and human leukocyte antigen typing kits for use in the pre- and post-transplant testing continuum. To revolutionise long-term patient care in transplantation, CareDx delivers cutting-edge surveillance management tools. Additionally, it offers patient care management, pharma services, cell transplant therapy, digital transplant solutions, and other things. The corporation has operations in Australia, Sweden, and the US. The U.S. company CareDx is based in South San Francisco, California. AlloMap and AlloSure Heart were combined to create Heartcare, which CareDx, Inc. unveiled in March 2018. Heartcare is a comprehensive diagnostic system that aids in the monitoring of heart patients.

Key Companies in the Heart Transplant market include

• Apaxis Medical, Inc.


• CardiacAssist Inc.


• SynCardia Systems, LLC


• Optum Inc.


• CARMAT


• HeartWare International Inc.


• Thoratec Corporation


• Calon Cardio

Heart Transplant Industry Developments

2021: To carry out an Early Feasibility Study (EFS) of its TAH in the US, CARMAT received FDA permission.

2020: The HeartMate 3 Heart Pump's modified labelling for use in paediatric patients with advanced, refractory left ventricular heart failure has been approved by the FDA.

2020: The Impella CP Heart Pumps from Abiomed were given the green light by the Ministry of Health, Labour, and Welfare (MHLW) in Japan.

Heart Transplant Market Segmentation

Heart Transplant Type Outlook

• Ventricular Assisted Device


• Others

Heart Transplant End User Outlook

• Hospitals


• Cardiac Institutes


• Others

Heart Transplant Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America